Skip to content
Heart icon (animated) heart icon (static)
Explore more Johnson & Johnson sites:
A graphic of the flag of Australia alt
A graphic of the flag of Argentina alt
A graphic of the flag of Brazil alt
A graphic of the flag of Chile alt
A graphic of the national flag of the People's Republic of China alt
A graphic of the national flag of Colombia alt
A graphic of the national flag of Ecuador alt
A graphic of the flag of Germany alt
A graphic of the national flag of India alt
A graphic of the national flag of Japan alt
A graphic of the flag of Mexico alt
A graphic of the flag of Paraguay alt
A graphic of the flag of Peru alt
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
A graphic of the national flag of Uruguay alt
A graphic of the flag of Venezuela alt
Share
Download Report
= Achieved

Pharmaceutical Pipeline – Key Events in 2022*

POTENTIAL APPROVALS US/EU

CABENUVA

HIV Adolescents
US

CARVYKTI (Ciltacabtagene autoleucel)

Relapsed refractory Multiple Myeloma
US
EU

IMBRUVICA (ibrutinib)

Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)
EU

IMBRUVICA (ibrutinib)

Pediatric Chronic Graft Versus Host Disease
US

STELARA (ustekinumab)

Pediatric jPSA
US

teclistamab (BCMA/CD3)

Relapsed Refractory Multiple myeloma
US

PLANNED SUBMISSIONS US/EU

aprocitentan

Difficult to treat hypertension
US

IMBRUVICA (ibrutinib)

Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (SHINE)
EU

IMBRUVICA (ibrutinib)

Pediatric Chronic Graft Versus Host Disease
US

niraparib

L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone
EU

teclistamab (BCMA/CD3)

Relapsed Refractory Multiple myeloma
EU

VAC18193

RSV Adult Vaccine
US

VAC31518

Janssen COVID-19 Vaccine
US

POTENTIAL CLINICAL DATA PRESENTATIONS

Phase II

BALVERSA (erdafitinib)

Tumor Agnostic (RAGNAR)

guselkumab

Ulcerative Colitis Monotherapy (QUASAR)

guselkumab/golimumab

Ulcerative Colitis (VEGA)

milvexian (factor Xla)

Secondary stroke prevention (AXIOMATIC-SSP)

SPRAVATO (esketamine)

Pediatric Major Depressive Disorder with Suicidal Ideation or behavior (DIRECTION)
Phase III

aprocitentan

Difficult to treat hypertension (PRECISION RHTT)

CARVYKTI (Ciltacabtagene autoleucel)

Relapsed refractory multiple myeloma w/1-3 PL (CARTITUDE-4)

DARZALEX (daratumumab)

Frontline multiple myeloma transplant ineligible (CEPHEUS)

IMBRUVICA (ibrutinib)

Relapsed/refractory Indolant Non-Hodgkins Lymphoma (SELENE)

niraparib

L1 Prostate cancer metastatic castration-resistant (MAGNITUDE)
*This information is accurate as of April 19, 2022 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue